HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use EVITHROM® safely and effectively. See full prescribing information for EVITHROM®.

EVITHROM® [Thrombin, Topical (Human)]
Lyophilized Powder for Solution

For topical use

Initial U.S. Approval: 2007

INDICATIONS AND USAGE

- EVITHROM® is a topical thrombin indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical (1).
- EVITHROM® may be used in conjunction with an Absorbable Gelatin Sponge, USP (1).

DOSAGE AND ADMINISTRATION

- For topical use only. DO NOT INJECT (2.2).
- Apply EVITHROM® on the surface of bleeding tissue only.
- The amount of EVITHROM® required depends upon the area of tissue to be treated and the method of application. In clinical studies, volumes up to 10 ml were used in conjunction with Absorbable Gelatin Sponge, USP (2.2).

DOSAGE FORMS AND STRENGTHS

EVITHROM® is a lyophilized powder for solution containing 2000 (1600–2400) units of human thrombin. After reconstituted, the final solution contains 1000 (800–1200) units/ml of EVITHROM® (3).

CONTRAINDICATIONS

- Do not use in individuals known to have an anaphylactic or severe systemic reaction to EVITHROM® or to human blood products (4).
- Do not use for treatment of severe or brisk arterial bleeding (4).

WARNINGS AND PRECAUTIONS

- Potential risk of thrombosis if absorbed systemically (5.1).
- May carry a risk of transmitting infectious agents such as viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite manufacturing steps designed to reduce the risk of viral transmission (5.2).
- Hypersensitivity reactions, including anaphylaxis, may occur (5.1).

ADVERSE REACTIONS

- The most common adverse reactions (incidence 2%) were prolonged activated partial thromboplastin time, increased INR, decreased lymphocyte count, prolonged prothrombin time and increased neutrophil count (6).
- None of the patients treated with EVITHROM® developed antibodies to human thrombin or to human Factor V/Va. The clinical significance of these findings is unknown (6).

To report SUSPECTED ADVERSE REACTIONS, contact ETHICON Customer Support Center at (877) 384-4266 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS

Animal Reproduction studies have not been conducted with EVITHROM®. EVITHROM® should only be used in pregnancy if clearly indicated (8.1).

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 1/2016
1 INDICATIONS AND USAGE
EVITHROM® Thrombin, Topical (Human), is indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical.

EVITHROM® Thrombin, Topical (Human), may be used in conjunction with an Absorbable Gelatin Sponge, USP.

2 DOSAGE AND ADMINISTRATION
2.1 Dose
For Topical Use Only. DO NOT INJECT.
The amount of EVITHROM® required depends upon the area of tissue to be treated and the method of application. As an approximate guide, volumes up to 10 ml were used in clinical studies where EVITHROM® was used in conjunction with Absorbable Gelatin Sponge, USP.

2.2 Preparation
- Use aseptic technique when handling vials and syringes.
- Remove the flip-off plastic cap from the vial to expose the rubber stopper.
- Reconstitute the lyophilized human thrombin powder with 2 ml of sterile Water for Injection, USP using the provided reconstitution device.
- Shake gently until the solution is clear.
- Reconstituted solution is stable for up to 8 hours at room temperature and should be used within this time period.

2.3 Application Techniques
Apply only on the surface of bleeding tissue.

EVITHROM® Use alone
- Sponge target surface (do not wipe) or suction free of blood before application.
- Flood the surface with EVITHROM® using a sterile syringe and small gauge needle.
- Avoid sponging after treatment, to ensure that the clot remains securely in place.

EVITHROM® in conjunction with Absorbable Gelatin Sponge, USP
- Prepare the desired shape of the Absorbable Gelatin Sponge, USP (see Absorbable Gelatin Sponge, USP circular for additional instructions for use).
- Transfer EVITHROM® into a sterile container using aseptic techniques.
- Immerse gelatin sponge into the EVITHROM® solution.
- Vigorously knead the sponge with moistened gloved fingers until all air is expelled and it can return to its original size and shape.
- Hold the saturated sponge in place with gauze or cotton pledget using moderate pressure until hemostasis is achieved.

3 DOSAGE FORMS AND STRENGTHS
EVITHROM® is a sterile lyophilized powder for solution 2000 (1600–2400) units of lyophilized human thrombin powder for reconstitution. After reconstituted, the final solution contains 1000 (800–1200) units/ml of human thrombin.

Potency, expressed in units, is determined using a clotting assay against an internal reference standard for potency that has been calibrated against the World Health Organisation (WHO) Second International Standard for Thrombin, 01/580. Therefore, a unit used herein is equivalent to an International Unit.

4 CONTRAINDICATIONS
- Do not use in individuals known to have an anaphylactic or severe systemic reaction to EVITHROM® or to human blood products.
- Do not use for the treatment of severe or brisk arterial bleeding.

5 WARNINGS AND PRECAUTIONS

5.1 Thrombosis
There is a risk of thrombosis if absorbed systemically. Apply topically only.

5.2 Anaphylactic/Hypersensitivity Reactions
Anaphylactic reactions may occur in rare cases. No adverse events of this type were reported during the conduct of the clinical trials. Severe hypotensive reactions require immediate intervention using current principles of shock therapy.

5.3 Transmission of Infectious Agents

Because this product is made from human plasma, it may carry a risk of transmitting infectious agents, such as viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk of transmitting an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections and by inactivating and removing certain viruses. Despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products.

6 ADVERSE REACTIONS

The most common adverse reactions during clinical trial (reported in at least 2% of subjects treated with EVITHROM®) were prolonged activated partial thromboplastin time, increased INR, decreased lymphocyte count, prolonged prothrombin time and increased neutrophil count.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug product cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In a multicenter, prospective, controlled, randomized, double-blinded clinical trial of 305 subjects where EVITHROM® (n=153) was compared with bovine thrombin (n=152), occurrence of adverse events was not statistically different between the two groups.

Overall, adverse events occurred in similar proportions of subjects in the two groups (see Table 1). No clinically significant differences were seen in age (<65 years, >65 years) or gender subgroup analyses of adverse events.

At least one serious adverse event (SAE) was reported for 26/153 (17%) subjects treated with human thrombin and 17/152 (11%) subjects treated with bovine thrombin. The SAEs reported were associated with post-surgical complications (e.g. wound infection 3/153 for EVITHROM® and 2/152 for bovine thrombin) and the medical condition of the subject and were not considered related to study drug. Two subjects (1.3%) in EVITHROM® group experienced a treatment emergent severe adverse event: respiratory arrest and post-procedural hematoma (in one subject) and extradural hematoma. Three subjects in the bovine thrombin group experienced a treatment emergent severe adverse event: hyperhidrosis, pyrexia and post-procedural hematoma.

No deaths were reported during the study period.

Viral serology was not monitored during the trial with EVITHROM®. However, no adverse events indicative of infection with transfusion-transmissible agents were reported.

<table>
<thead>
<tr>
<th>System Organ Class/Adverse Event</th>
<th>EVITHROM® (n=153)</th>
<th>Bovine (n=152)</th>
<th>Total (n=305)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigations</td>
<td>11 (7.2%)</td>
<td>14 (9.2%)</td>
<td>25 (8.2%)</td>
</tr>
<tr>
<td>Activated partial thromboplastin time increased</td>
<td>4 (2.6%)</td>
<td>8 (5.3%)</td>
<td>12 (3.9%)</td>
</tr>
</tbody>
</table>
In the clinical study, serum samples were collected at baseline and at 5 weeks post-surgery for evaluation of antibodies to bovine thrombin, bovine Factor V/Va, human thrombin, and human Factor V/Va. Samples were collected at both time points for 81.3% of the subjects. The ELISA data were adjudicated by a panel of experts blinded to treatment assignment. After reviewing all data, the panel used an algorithm for assigning outcomes for each antigen: seroconversion negative or seroconversion positive.

The protocol did not specify any comparative analysis for immunogenicity data, only descriptive statistics. The adjudicated results show that 3.3% of the subjects treated with EVITHROM® (frozen formulation) developed antibodies to any of the four antigens, compared to 12.7% of the subjects developing antibodies in the control group (bovine thrombin). 7.9% of the subjects treated with bovine thrombin (control group) developed antibodies to bovine thrombin and 9.5% of these subjects developed antibodies to bovine Factor V/Va. A few control subjects had antibodies that cross-reacted with human thrombin, but none had antibodies that cross-reacted with human Factor V/Va. None of the patients treated with EVITHROM® developed detectable antibodies to human thrombin or to human Factor V/Va.

The detection of antibody formation is highly dependent upon the sensitivity and specificity of the assay. The observed incidence of a positive signal in an assay may be influenced by several factors including timing of sampling, sample handling, concomitant medications, or underlying disease. Therefore, direct comparison of incidence of antibody development to human thrombin, bovine thrombin, human Factor V/Va or bovine Factor V/Va following administration of EVITHROM® with incidence of antibody development following administration of other products may be misleading and the clinical significance of these findings is unknown.

6.2 Post Marketing Experience
No adverse reactions have been identified from spontaneous post-marketing reports.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy
Pregnancy Category C. Animal reproduction studies have not been conducted with EVITHROM®. It is also not known whether EVITHROM® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. EVITHROM® should be given to a pregnant woman only if clearly needed.

Evaluation of the reproduction and development toxicity has been limited to the evaluation of embryo-fetal development of TnBP and Triton X-100 formulated in saline in rat and rabbit (see Section 13 NONCLINICAL TOXICOLOGY for more information).
8.2 Labor and Delivery
The safety of EVITHROM® for use during labor and delivery has not been established.

8.3 Nursing Mothers
The safety of EVITHROM® for use during breast-feeding has not been established. Use only if clearly needed.

8.4 Pediatric Use
Of the 155 patients undergoing liver surgery who were treated in adequate and well-controlled studies of EVICEL® Fibrin Sealant (Human), in which EVITHROM® is a component, eight were pediatric patients. Of these, five were less than 2 years old and three were between 2 and 12 years old. Use of EVITHROM® in pediatric patients is supported by these data and by extrapolation of findings for safety and efficacy in adults.

8.5 Geriatric Use
Sixty three (63) subjects over 65 years of age received EVITHROM® in the clinical trial. No differences in safety or effectiveness were observed between the elderly and younger patients. Greater susceptibility of older patients to adverse reactions cannot be ruled out.

11 DESCRIPTION
EVITHROM® is a sterile lyophilized powder of purified human thrombin (1600–2400 units) of white to slightly yellowish color. When reconstituted, EVITHROM® solution, pH 6.8–7.2, is clear to slightly opalescent and colorless to slightly yellowish. Other inactive ingredients are Calcium chloride, Human albumin, Mannitol, Sodium acetate.

EVITHROM® is made from pooled Human Source obtained from US licensed plasma collection centers. Individual plasma units obtained for production of EVITHROM® are tested by licensed serological tests for HBsAg, HIV 1 & 2 Ab and HCV Ab. Additionally, the plasma units are tested by licensed Nucleic Acid Testing (NAT) for HIV-1, HCV, HBV, HAV and parvovirus B19. All tests for HIV, HCV, HBV and HAV must be negative (non-reactive). However, since the effectiveness of the HBV and HAV NAT methods in detecting low levels of viral material is still under investigation, the significance of a negative result for these viruses is unknown. The level of parvovirus B19 contamination is not permitted to exceed 10,000 copies/ml. This limit is applied to restrict the viral load of parvovirus B19 in the starting plasma pool. In addition to the screening of plasma units, each manufacturing pool is tested for HBsAg, HIV-1 & 2 Ab, HCV NAT and for parvovirus B19 by NAT. Manufacturing pool testing, however, is of lower sensitivity than individual unit testing.

EVITHROM® is manufactured by chromatographic purification of prothrombin from cryo-poor plasma followed by activation with calcium chloride. The manufacturing process includes two targeted steps for inactivation or removal of viruses. The first of these is treatment with a solvent/detergent (S/D) mixture (1% tri-n-butyl phosphate, 1% Triton X-100) for 6 hours at 26°C to inactivate lipid enveloped viruses. The S/D reagents are removed by cation exchange chromatography. Mannitol and human albumin are used to stabilize the solution, which undergoes nanofiltration for removal of both enveloped and non-enveloped viruses. After nanofiltration, the solution is formulated with calcium chloride, sterile filtered and aseptically filled and frozen.

The effectiveness of the S/D treatment and nanofiltration procedures for reducing virus content has been assessed using a series of viruses with a range of physico-chemical characteristics. The results of the validation studies are summarized in Table 2.

Table 2: Reducing factors of S/D treatment and nanofiltration for a series of viruses
<table>
<thead>
<tr>
<th>Virus</th>
<th>HIV-1</th>
<th>SBV</th>
<th>BVDV</th>
<th>PRV</th>
<th>EMCV</th>
<th>HAV</th>
<th>MVM</th>
<th>Reduction factor (log_{10})</th>
</tr>
</thead>
<tbody>
<tr>
<td>SD Treatment</td>
<td>&gt;5.8</td>
<td>&gt;5.0</td>
<td>&gt;4.6</td>
<td>&gt;4.2</td>
<td>Not Done</td>
<td>Not Done</td>
<td>Not Done</td>
<td></td>
</tr>
<tr>
<td>Nanofiltration</td>
<td>&gt;4.6</td>
<td>Not Done</td>
<td>&gt;5.6</td>
<td>&gt;5.7</td>
<td>&gt;7.4</td>
<td>&gt;7.5</td>
<td>&gt;6.3</td>
<td></td>
</tr>
<tr>
<td>Global Reduction Factor</td>
<td>&gt;10.4</td>
<td>&gt;5.0</td>
<td>&gt;10.2</td>
<td>&gt;9.9</td>
<td>&gt;7.4</td>
<td>&gt;7.5</td>
<td>&gt;6.3</td>
<td></td>
</tr>
</tbody>
</table>

HIV-1: Human Immunodeficiency Virus Type 1  
SBV: Sindbis Virus  
BVDV: Bovine Viral Diarrhea Virus  
PRV: Pseudorabies Virus  
EMCV: Encephalomyocarditis Virus  
HAV: Hepatitis A Virus  
MVM: Minute Virus of Mouse

12 CLINICAL PHARMACOLOGY

EVITHROM® requires no intermediate physiological agent because it clots the fibrinogen of the blood directly. Failure to clot blood occurs in the rare case where the primary clotting defect is the absence of fibrinogen itself. The speed with which thrombin clots blood is dependent upon the concentration of both thrombin and fibrinogen.

12.1 Mechanism of Action

Thrombin (coagulation Factor IIa) is a highly specific protease that transforms plasma fibrinogen into fibrin which, in the presence of Factor XIII in the patient's plasma, is cross-linked to form a stable clot. When applied to a surgical wound where bleeding is present, thrombin activates fibrinogen in the patient's plasma to form fibrin, which results in clot formation and hemostasis. The fibrin clot is stabilized by cross-linking occurring as a result of activation of the patient's endogenous Factor XIII, which requires the presence of calcium.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term animal studies have not been performed to evaluate the carcinogenic potential of EVITHROM® due to the human origin of thrombin.

Studies were performed in bacteria to determine mutagenicity of human thrombin alone, and solvent/detergent residues [tri-n-butyl phosphate (TnBP) and Triton X-100], used in the virus inactivation manufacturing step. These studies were negative for both thrombin and for TnBP or Triton X-100 at all concentrations tested. All concentrations of the combination of TnBP and Triton X-100 also tested negative in assays performed to determine mammalian cell mutagenicity, chromosomal aberrations and micronuclei induction.

The effect of EVITHROM® on fertility has not been evaluated. Reproductive studies were performed in rats with the combination of solvent detergent impurities, TnBP and Triton X-100 at doses up to approximately 600-fold human dose of TnBP (900 μg/kg/day) and 3000-fold human dose of Triton X-100 (4500 μg/kg/day) resulted in increased post-implantation loss and an increased number of late resorptions. Other studies performed with combinations of TnBP (300-fold human dose, 450 μg/kg/day) and Triton X-100 (1500-fold human dose, 2250 μg/kg/day) resulted in increased resorption rates,
decreased fetal body weights, and an increased number of runts. No embryo-fetal adverse effects were observed at doses up to 300 μg/kg/day TnBP and 1500 μg/kg/day Triton X-100, 200-fold and 1000-fold the human dose, respectively.

13.2 Animal Toxicology and/or Pharmacology

EVICEL® Fibrin Sealant (Human), which includes EVITHROM® as one of the active components, was classified as non-irritant in the Primary Cutaneous Irritation Test and slightly irritant in the Ocular Irritation test.

Neurotoxicity studies performed with EVITHROM® or with EVICEL® confirmed that intracerebral application of thrombin was not associated with any evidence of neurotoxicity.

No toxicological effects due to solvent/detergent reagents [tri-n-butyl phosphate (TnBP) and Triton X-100] used in the virus inactivation procedure are expected since the residual levels are less than 5 μg/ml.

14 CLINICAL STUDIES

EVITHROM® was compared with bovine thrombin in a multicenter, prospective, randomized, controlled, double-blinded clinical trial of 305 subjects at 22 centers in the US. Subjects undergoing elective cardiovascular, neurologic (spinal) or general surgical procedures were randomized (stratified by surgical specialty) when there was oozing or bleeding of mild intensity that could not be controlled by other surgical techniques and the surgeon determined that a topical hemostatic agent was necessary. Bovine thrombin and EVITHROM® were applied with SURGIFOAM® Absorbable Gelatin Sponge, USP.

Treatment with EVITHROM® was comparable to treatment with bovine thrombin in achieving hemostasis within:

- 10 minutes of product application and
- 6 and 3 minutes of product application.

### Table 3: Efficacy for Intent to Treat (ITT) population

<table>
<thead>
<tr>
<th>Time Interval</th>
<th>Treatment Group: # Successes/N (%)</th>
<th>Ratio Human/Bovine</th>
<th>95% CI for Ratio Human/Bovine *,†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EVITHROM® N=153</td>
<td>Bovine thrombin N=152</td>
<td></td>
</tr>
<tr>
<td>10 minutes</td>
<td>149/153 (97.4)</td>
<td>148/152 (97.4)</td>
<td>1.00</td>
</tr>
<tr>
<td>6 minutes</td>
<td>145/153 (94.8)</td>
<td>141/152 (92.8)</td>
<td>1.02</td>
</tr>
<tr>
<td>3 minutes</td>
<td>112/153 (73.2)</td>
<td>110/152 (72.4)</td>
<td>1.01</td>
</tr>
</tbody>
</table>

* 95% CI is for the ratio of proportions of success
† For the two treatments to be equivalent, both limits of the confidence interval must have been within (0.80, 1.25)

### Table 4: Efficacy at 6 minutes (ITT population)

<table>
<thead>
<tr>
<th>Surgical Specialty</th>
<th>Treatment Group: # Successes/N (%)</th>
<th>Ratio Human/Bovine</th>
<th>95% CI for Ratio Human/Bovine *,†</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVITHROM®</td>
<td>Bovine thrombin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Cardiovascular | 44/47 (93.6) | 38/46 (82.6) | 1.13 | 0.97, 1.36
Neurosurgical (Spine) | 60/61 (98.4) | 59/60 (98.3) | 1.00 | 0.93, 1.08
General Surgery | 41/45 (91.1) | 44/46 (95.7) | 0.95 | 0.82, 1.08
Overall | 145/153 (94.8) | 141/152 (92.8) | 1.02 | 0.96, 1.09

* 95% CI is for the ratio of proportions of success
† For the two treatments to be equivalent, both limits of the confidence interval must have been within (0.80, 1.25)

At the 6 minute and 10 minute time points, >90% of subjects from all surgeries in both study groups had achieved hemostasis. The following results were documented for the 3 minute time point as stratified by surgery and study treatment: (1) cardiovascular surgery – human thrombin: 61.7%; bovine thrombin: 63.0%, (2) spinal surgery – human thrombin: 83.6%; bovine thrombin: 80.0%, (3) general surgery – human thrombin: 71.1%; bovine thrombin: 71.7% for an overall ratio of proportions of 1.01.

16 HOW SUPPLIED/STORAGE AND HANDLING

EVITHROM® is supplied in a single-use 2 ml vial containing 2000 (1600–2400) units of lyophilized human thrombin powder for reconstitution in 2 ml Water for Injection, USP. NDC 63713-461-02

- Store EVITHROM® powder vials at 2–25°C (36–77°F) for up to 2 years.
- Discard if the packaging of EVITHROM® is damaged.
- Keep the vials protected from light.
- Store reconstituted EVITHROM® solution at room temperature for up to 8 hours.
- Do not freeze or refrigerate EVITHROM® once it has been reconstituted.
- Discard unused contents.

17 PATIENT COUNSELING INFORMATION

Inform patients of the following:
- Some viruses such as hepatitis A virus and parvovirus B19 are particularly difficult to remove or inactivate. Parvovirus B19 most seriously affects pregnant women or immune-compromised individuals. Symptoms of parvovirus B19 infection include: fever, drowsiness, chills and runny nose followed about two weeks later by a rash and joint pain. Evidence of hepatitis A may include several days to weeks of poor appetite, fatigue and low-grade fever followed by nausea, vomiting and abdominal pain. Dark urine and a yellowed complexion are also common symptoms. Consult your physician if such symptoms appear.
- If absorbed systemically EVITHROM® could potentially cause blood clotting disorders. Consult your physician if leg tenderness or swelling, chest pain, or shortness of breath appears.

Distributed by:

Ethicon, Inc.
P.O. Box 151, Somerville,
NJ 08876-0151 USA

Manufactured by:
THROMBIN TOPICAL (HUMAN)

EVITHROM® Lyophilized Powder

NDC-63713-461-02

This bottle contains 2000 (1600-2400) units of lyophilized powder of Thrombin (human), calcium chloride, albumin (human), mannitol and sodium acetate. Store unopened Vial at 2-25°C. Reconstitute in 2mL of Water for Injection, USP to obtain 1000 (800-1200) units/ml. Do not freeze or refrigerate once reconstituted. Vials are for single use only. Discard unused contents. Protect from light. See enclosed instructions.
HUMAN THROMBIN (UNII: 6K15ABL77G) (HUMAN THROMBIN - UNII:6K15ABL77G)  HUMAN THROMBIN  2000 [IU] in 2 mL

Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>CALCIUM CHLORIDE (UNII: M4I0D6VV5M)</td>
<td></td>
</tr>
<tr>
<td>ALBUMIN HUMAN (UNII: ZIF514RVZR)</td>
<td></td>
</tr>
<tr>
<td>MANNITOL (UNII: 3OWL53L36A)</td>
<td></td>
</tr>
<tr>
<td>SODIUM ACETATE (UNII: 4550K0SC9B)</td>
<td></td>
</tr>
</tbody>
</table>

Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:63713-461-02</td>
<td>2 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLA</td>
<td>BLA125247</td>
<td>09/19/2009</td>
<td></td>
</tr>
</tbody>
</table>

Labeler - Ethicon, Inc (002144145)

Registrant - Omrix Biopharmaceuticals Ltd (514577949)

Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>CILAG AG</td>
<td></td>
<td>483237103</td>
<td>manufacture, analysis, label, pack</td>
</tr>
</tbody>
</table>

Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omrix Biopharmaceuticals Ltd</td>
<td></td>
<td>514577949</td>
<td>analysis, api manufacture, manufacture, label, pack</td>
</tr>
</tbody>
</table>

Revised: 2/2019